All articles tagged with #attr cm
AstraZeneca disclosed a Phase 3 failure of its ATTR-CM silencer, which produced no extra benefit for patients already on a stabilizer, a result that may tilt the market toward stabilizers and ripple through rivals like Alnylam and BridgeBio.
At the European Society of Cardiology Congress in Munich, Alnylam's ATTR-CM therapies face new headwinds as data from rival drug eplontersen suggest it failed to significantly reduce cardiovascular deaths or recurrent events, potentially reshaping expectations for Alnylam and informing investors and clinicians about the competitive landscape.
AstraZeneca and Ionis reported that their heart-disease drug Wainua failed to outperform placebo in a pivotal trial for ATTR-CM (transthyretin-mediated amyloid cardiomyopathy), not reducing cardiovascular death or clinical events, and the news pushed both companies' shares down in premarket trading.
The FDA has approved BridgeBio's new drug, Attruby, for treating transthyretin amyloid cardiomyopathy (ATTR-CM), marking the first new treatment for this heart condition in over five years. ATTR-CM, which affects over 400,000 people globally, is caused by genetic mutations or aging, leading to amyloid deposits in the heart that impair its function. This approval represents BridgeBio's first major commercial product.
BridgeBio has announced positive results from its Phase III trial of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The trial showed improvements in mortality, cardiovascular-related hospitalizations, a six-minute walk test, and a biomarker of the disease. Patients receiving the drug had an 81% survival rate at 30 months, compared to 74% on placebo, and the drug reduced hospitalization rates by 50%.